Eugenol suppresses VEGF-dependent angiogenesis by JAK2/STAT3 pathway in non-small cell lung cancer  

作　　者：Yifan Su Yurong Wang Qian Yu Zhijian Wu Dawei Zhang Chunyan Yan 

机构地区：[1]School of Pharmacy,Guangdong Pharmaceutical University,Guangzhou,China [2]Department of Chinese Medicine,Guangzhou First People’s Hospital,School of Medicine,South China University of Technology,Guangzhou,China

出　　处：《Guideline and Standard in Chinese Medicine》2024年第2期80-90,共11页中医规范与标准(英文)

基　　金：funded by the National Natural Science Foundation of China(No.81973454);the Guangzhou Science and Technology Plan Project(No.202102020312).

摘　　要：Background:Non-small cell lung cancer(NSCLC)is a highly vascularized solid tumor,and tumor angiogenesis is closely associated with the metastasis and progression of NSCLC.Antiangiogenic drugs can target the tumor microenvironment to degrade existing tumor blood vessels while inhibiting tumor angiogenesis and have become one of the indispensable treatments for patients with advanced NSCLC.Although various new drugs have been tested in different settings of NSCLC,none of them have shown the desired therapeutic effects so far.Therefore,the search for new and effective therapeutic modalities has become a new goal for treating NSCLC.Objective:Eugenol is a phenolic aromatic compound derived from Eugenia caryophyllata,Cinnamomum cassia,etc.,which has historically been used for various medical purposes.Studies have shown that eugenol exhibits significant anticancer effects against several types of cancer;however,its therapeutic effect on angiogenesis remains a mystery.In this study,the in vitro and in vivo antiangiogenic effects of eugenol in NSCLC and the underlying molecular mechanism were explored,which could provide a promising strategy for the treatment of NSCLC.Methods:The effects of eugenol on the proliferative capacity of human umbilical vein endothelial cells(HUVECs)and A549 cells were examined by methyl thiazolyl tetrazolium assay.The migration and invasion of eugenol-treated HUVECs were evaluated by woundinghealing and transwell assay,and the angiogenesis was measured by tube formation assay.The expression of angiogenesis-related genes and proteins,as well as the JAK2/STAT3 pathway,was evaluated by real-time quantitative PCR and western blot.Flow cytometry was performed to detect the effect of eugenol on the apoptotic profile of A549 cells.Finally,the A549 tumor-bearing nude mice were constructed to evaluate the in vivo anti-NSCLC activity of eugenol.Results:Eugenol inhibited the migration,invasion,and tube formation of HUVECs.Meanwhile,eugenol blocked the phosphorylation of vascular endothelial growth factor

关 键 词：EUGENOL ANGIOGENESIS non-small cell lung cancer JAK2/STAT3 

分 类 号：R73[医药卫生—肿瘤]